人体表皮生长因子受体2-低乳腺癌:病理学家之间的患病率和评分一致性
Maher Sughayer1, Ghada Al-Jussani2, Ahmed Salem3
1Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Breast cancer : basic and clinical research
|August 27, 2025
概括
在约旦, 低HER2乳腺癌很常见, 病理学家在评分方面表现出很大一致. 这一发现对于针对大量患者的抗HER2治疗决定至关重要.
科学领域:
- 癌症学
- 病理学
- 遗传学
背景情况:
- 新兴的抗HER2疗法有利于低表皮生长因子受体2 (HER2) 的乳腺癌.
- 这项研究调查了约旦低HER2乳腺癌的流行率和病理学家评分的一致性.
研究的目的:
- 为了确定低HER2乳腺癌的患病率.
- 使用2018年ASCO/CAP指南评估HER2评分中的病理学间一致性.
主要方法:
- 对116个乳腺癌样本进行了回顾性观察研究.
- 3名病理学家使用2018年ASCO/CAP指南进行独立的HER2评分.
- 使用弗莱斯卡帕和科恩加权卡帕统计的对应性分析.
主要成果:
- 低HER2瘤 (1+或2+IHC与负FISH) 占72. 4%的病例.
- 观察到实质性的病理学家间一致性 (科恩的卡帕为0. 691- 0. 849,弗莱斯的卡帕为0. 645).
- 病理学家在67.2%的病例中达成完全一致.
结论:
- 在约旦人口中,低HER2乳腺癌的患病率很高.
- 在HER2评分方面存在大量病理学家间的共识,支持可靠的临床应用.
- 这些发现强调了在约旦针对性治疗中标准化HER2评估的重要性.
更多相关视频
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.1K
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
273
相关概念视频
Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
